Year All20242023202220212020201920182017201620152014 ABIVAX Reports Impressive 12-month Efficacy and Safety Data from ABX464 Ulcerative Colitis Maintenance Study at United European Gastroenterology Conference October 21, 2019 Read More ABIVAX Announces That It Has Been Selected to Present a Late-Breaking Abstract on ABX464 in Ulcerative Colitis at UEG Week 2019 October 09, 2019 Read More ABIVAX Announces the Release of Its 2019 Half-year Financial Report September 30, 2019 Read More ABIVAX First-Half 2019 Financial Results and Operations Update September 19, 2019 Read More First Patient Enrolled in Abivax ABX464-103 Phase 2b Clinical Trial in Patients with Ulcerative Colitis August 19, 2019 Read More Abivax Treats First Patient in Phase 2a Rheumatoid Arthritis Clinical Trial of ABX464 August 01, 2019 Read More Webcast: ABIVAX Completes €12 Million Capital Raise Entirely Subscribed by Sofinnova Partners at Market Price July 15, 2019 Read More ABIVAX Completes €12 Million Capital Raise Entirely Subscribed by Sofinnova Partners at Market Price July 11, 2019 Read More Abivax Receives First Clinical Trial Authorization for ABX464 Phase 2a Study in Patients with Rheumatoid Arthritis June 04, 2019 Read More Abivax Delivered Oral Presentation at Leading US International Gastroenterology Conference on ABX464 Phase 2a Nine-month Maintenance Data Demonstrating Long Term Efficacy and Safety in Ulcerative Colitis May 22, 2019 Read More
ABIVAX Reports Impressive 12-month Efficacy and Safety Data from ABX464 Ulcerative Colitis Maintenance Study at United European Gastroenterology Conference October 21, 2019 Read More
ABIVAX Announces That It Has Been Selected to Present a Late-Breaking Abstract on ABX464 in Ulcerative Colitis at UEG Week 2019 October 09, 2019 Read More
First Patient Enrolled in Abivax ABX464-103 Phase 2b Clinical Trial in Patients with Ulcerative Colitis August 19, 2019 Read More
Abivax Treats First Patient in Phase 2a Rheumatoid Arthritis Clinical Trial of ABX464 August 01, 2019 Read More
Webcast: ABIVAX Completes €12 Million Capital Raise Entirely Subscribed by Sofinnova Partners at Market Price July 15, 2019 Read More
ABIVAX Completes €12 Million Capital Raise Entirely Subscribed by Sofinnova Partners at Market Price July 11, 2019 Read More
Abivax Receives First Clinical Trial Authorization for ABX464 Phase 2a Study in Patients with Rheumatoid Arthritis June 04, 2019 Read More
Abivax Delivered Oral Presentation at Leading US International Gastroenterology Conference on ABX464 Phase 2a Nine-month Maintenance Data Demonstrating Long Term Efficacy and Safety in Ulcerative Colitis May 22, 2019 Read More
